MacroGenics, Inc. (MGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
4.29 USD
-0.21
(-4.667%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:55 a.m. EDT
The investment case here is defined by a stark disconnect between the company's deteriorating fundamentals and aggressive speculative positioning. Fundamentally, the business is in distress: revenues have collapsed by 65% year-over-year, gross margins are deeply negative, and the stock has lost 94% of its value over the last nine years. The balance sheet shows significant losses and negative operating cash flow, making a 'value trap' diagnosis appropriate for a long-term holder. However, the short-term outlook is driven entirely by options flow rather than earnings. Traders are pouring capital into calls at strikes like $7.00, suggesting a belief in a specific catalyst—likely related to the ADC pipeline or the recent Sanofi payment—that could force a re-rating. While the statistical forecast model offers no meaningful directional signal due to low confidence, the options market is screaming for a bounce. This creates a high-risk scenario where the stock could rally on hype before the fundamental reality of shrinking revenues sets in again. |
| Model | MAE |
|---|---|
| MSTL_52 ✓ | 0.127943 |
| MSTL_52_70 | 0.144676 |
| MSTL | 0.163112 |
| AutoARIMA | 0.170167 |
| MSTL_70 | 0.184294 |
| AutoTheta | 0.192892 |
| AutoETS | 0.212482 |
Forecast horizon: 60 days | Selected: MSTL_52
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 2.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.366 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 172.229 |
| Revenue per Share | 2.482 |
| Market Cap | 272,685,792 |
| Forward P/E | -3.04 |
| Beta | 1.18 |
| Profit Margins | -44.79% |
| Website | https://www.macrogenics.com |
As of July 11, 2026, 6:55 a.m. EDT: Speculators are overwhelmingly bullish, positioning heavy call volume and open interest at strikes significantly above the current price ($5.00, $7.00). The ratio of out-of-the-money call volume to put volume is extreme, indicating a speculative bet on a rapid recovery or catalyst-driven surge rather than a hedging strategy.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0201342 |
| Address1 | 9,704 Medical Center Drive |
| All Time High | 41.0 |
| All Time Low | 0.99 |
| Ask | 5.47 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 885,740 |
| Average Daily Volume3 Month | 1,141,650 |
| Average Volume | 1,141,650 |
| Average Volume10Days | 885,740 |
| Beta | 1.179 |
| Bid | 3.25 |
| Bid Size | 2 |
| Book Value | 0.334 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.29 |
| Current Ratio | 1.902 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.52 |
| Day Low | 4.27 |
| Debt To Equity | 172.229 |
| Display Name | MacroGenics |
| Earnings Call Timestamp End | 1,742,502,600 |
| Earnings Call Timestamp Start | 1,742,502,600 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -56,568,000 |
| Ebitda Margins | -0.36012 |
| Enterprise To Ebitda | -2.739 |
| Enterprise To Revenue | 0.987 |
| Enterprise Value | 154,965,792 |
| Eps Current Year | 0.035 |
| Eps Forward | -1.41333 |
| Eps Trailing Twelve Months | -1.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 301 251 5321 |
| Fifty Day Average | 4.103 |
| Fifty Day Average Change | 0.1869998 |
| Fifty Day Average Change Percent | 0.045576356 |
| Fifty Two Week Change Percent | 202.01343 |
| Fifty Two Week High | 5.08 |
| Fifty Two Week High Change | -0.78999996 |
| Fifty Two Week High Change Percent | -0.15551181 |
| Fifty Two Week Low | 1.29 |
| Fifty Two Week Low Change | 3.0 |
| Fifty Two Week Low Change Percent | 2.3255816 |
| Fifty Two Week Range | 1.29 - 5.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,381,411,800,000 |
| Float Shares | 52,441,483 |
| Forward Eps | -1.41333 |
| Forward P E | -3.0353847 |
| Free Cashflow | 10,108,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 293 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.16236 |
| Gross Profits | -25,504,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03426 |
| Held Percent Institutions | 0.71079004 |
| Implied Shares Outstanding | 63,563,123 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. |
| Long Name | MacroGenics, Inc. |
| Market | us_market |
| Market Cap | 272,685,792 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_600911 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -70,358,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 286,034,053 |
| Number Of Analyst Opinions | 4 |
| Open | 4.51 |
| Operating Cashflow | -69,961,000 |
| Operating Margins | -1.6095799 |
| Payout Ratio | 0.0 |
| Phone | 301 251 5172 |
| Pre Market Change | 0.24000025 |
| Pre Market Change Percent | 5.5944114 |
| Pre Market Price | 4.53 |
| Pre Market Time | 1,784,108,750 |
| Previous Close | 4.5 |
| Price Eps Current Year | 122.57143 |
| Price Hint | 4 |
| Price To Book | 12.844312 |
| Price To Sales Trailing12 Months | 1.7359344 |
| Profit Margins | -0.4479 |
| Quick Ratio | 1.716 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.21 |
| Regular Market Change Percent | -4.66667 |
| Regular Market Day High | 4.52 |
| Regular Market Day Low | 4.27 |
| Regular Market Day Range | 4.27 - 4.52 |
| Regular Market Open | 4.51 |
| Regular Market Previous Close | 4.5 |
| Regular Market Price | 4.29 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 1,279,751 |
| Return On Assets | -0.17984 |
| Return On Equity | -1.40271 |
| Revenue Growth | 0.575 |
| Revenue Per Share | 2.482 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 63,563,123 |
| Shares Percent Shares Out | 0.1043 |
| Shares Short | 6,626,533 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,977,397 |
| Short Name | MacroGenics, Inc. |
| Short Percent Of Float | 0.108100004 |
| Short Ratio | 5.4 |
| Source Interval | 15 |
| State | MD |
| Symbol | MGNX |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.75 |
| Target Median Price | 7.0 |
| Total Cash | 154,228,992 |
| Total Cash Per Share | 2.426 |
| Total Debt | 36,509,000 |
| Total Revenue | 157,083,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.552425 |
| Two Hundred Day Average Change | 1.737575 |
| Two Hundred Day Average Change Percent | 0.6807546 |
| Type Disp | Equity |
| Volume | 1,279,751 |
| Website | https://www.macrogenics.com |
| Zip | 20,850 |